Literature DB >> 16111477

In vivo evidence of CHIP up-regulation attenuating tau aggregation.

Naruhiko Sahara1, Miyuki Murayama, Tatsuya Mizoroki, Makoto Urushitani, Yuzuru Imai, Ryosuke Takahashi, Shigeo Murata, Keiji Tanaka, Akihiko Takashima.   

Abstract

The carboxyl terminus of heat-shock cognate (Hsc)70-interacting protein (CHIP) is a ubiquitin E3 ligase that can collaborate with molecular chaperones to facilitate protein folding and prevent protein aggregation. Previous studies showed that, together with heat-shock protein (Hsp)70, CHIP can regulate tau ubiquitination and degradation in a cell culture system. Ubiquitinated tau is one component in neurofibrillary tangles (NFTs), which are a major histopathological feature of Alzheimer's disease (AD). However, the precise sequence of events leading to NFT formation and the mechanisms involved remain unclear. To confirm CHIP's role in suppressing NFT formation in vivo, we performed a quantitative analysis of CHIP in human and mouse brains. We found increased levels of CHIP and Hsp70 in AD compared with normal controls. CHIP levels in both AD and controls corresponded directly to Hsp90 levels, but not to Hsp70 or Hsc70 levels. In AD samples, CHIP was inversely proportional to sarkosyl-insoluble tau accumulation. In a JNPL3 mouse brain tauopathy model, CHIP was widely distributed but weakly expressed in spinal cord, which was the most prominent region for tau inclusions and neuronal loss. Protein levels of CHIP in cerebellar regions of JNPL3 mice were significantly higher than in non-transgenic littermates. Human tau was more highly expressed in this region of mouse brains, but only moderate levels of sarkosyl-insoluble tau were detected. This was confirmed when increased insoluble tau accumulation was found in mice lacking CHIP. These findings suggest that increases in CHIP may protect against NFT formation in the early stages of AD. If confirmed, this would indicate that the quality-control machinery in a neuron might play an important role in retarding the pathogenesis of tauopathies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111477     DOI: 10.1111/j.1471-4159.2005.03272.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  88 in total

1.  Parkin mediates the degradation-independent ubiquitination of Hsp70.

Authors:  Darren J Moore; Andrew B West; Dustin A Dikeman; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

2.  The ubiquitin ligase E6-AP is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of Hsp70-bound misfolded proteins.

Authors:  Amit Mishra; Swetha K Godavarthi; Megha Maheshwari; Anand Goswami; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

Review 3.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

Review 4.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

Review 6.  Role of ubiquitin protein ligases in the pathogenesis of polyglutamine diseases.

Authors:  Priyanka Dikshit; Nihar Ranjan Jana
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

7.  CHIP controls necroptosis through ubiquitylation- and lysosome-dependent degradation of RIPK3.

Authors:  Jinho Seo; Eun-Woo Lee; Hyerim Sung; Daehyeon Seong; Yves Dondelinger; Jihye Shin; Manhyung Jeong; Hae-Kyung Lee; Jung-Hoon Kim; Su Yeon Han; Cheolju Lee; Je Kyung Seong; Peter Vandenabeele; Jaewhan Song
Journal:  Nat Cell Biol       Date:  2016-02-22       Impact factor: 28.824

Review 8.  Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Authors:  Qian Huang; Maria E Figueiredo-Pereira
Journal:  Apoptosis       Date:  2010-11       Impact factor: 4.677

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.